GlassScriptPhysician profile
Baret Thomas Bercier
NPI 1164819231
$2,822.59
in general payments reported to CMS, 2019-2025
26 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $243 · 2021: $258 · 2022: $359 · 2023: $321 · 2024: $663 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.52 |
| Education | $147.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,098.91 | 2020-2025 | Linzess, Rinvoq, Mavyret |
| Pfizer INC. | $310.08 | 2020-2025 | |
| Janssen Biotech, INC. | $164.50 | 2023-2024 | Stelara, Tremfya |
| Redhill Biopharma INC. | $146.60 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $143.18 | 2019-2022 | |
| Celgene Corporation | $98.41 | 2023-2024 | Zeposia |
| 3-D Matrix, INC. | $91.97 | 2024 | |
| Genzyme Corporation | $87.79 | 2024-2025 | |
| Novo Nordisk INC | $81.95 | 2025 | Wegovy |
| Olympus Corporation of The Americas | $71.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.50 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $62.47 | 2024 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $59.38 | 2025 | |
| Erbe USA INC | $50.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $40.58 | 2023-2025 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $34.31 | 2025 | Givlaari |
| Ardelyx, INC. | $30.85 | 2025 | Ibsrela |
| Covidien LP | $29.90 | 2019 | |
| Conmed Corporation | $23.81 | 2025 | Conmed Biliary |
| Daiichi Sankyo INC. | $23.80 | 2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $21.99 | 2022 | |
| Amgen INC. | $21.46 | 2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $20.05 | 2025 | Eohilia |
| Ferring Pharmaceuticals INC. | $15.58 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $15.02 | 2024 | Voquezna |
| Olympus America INC. | $14.09 | 2024 | Evis Exera III Colonovideoscope |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baret Bercier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.